CNTX$0.1966-2.67%
Context Therapeutics Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$18.06M
Float & O/S:
Inst Own:
DilutionScan read 26 of Context Therapeutics Inc.'s SEC filings and found 4 warrant series, 1 ATM program and 3 shelf registrations on file for CNTX. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 4, 2026.
Signal8 Summary
CNTX
Pre-revenue biotech burning cash
Snapshot
Context Therapeutics is a clinical-stage biotech focused on cancer treatments that currently generates no revenue and burns through cash to fund research.
What's Happening Right Now
- : Context Therapeutics was added to the Russell 2000 and Russell 3000 indexes, a move that typically brings passive investment inflows from index funds.
- : Context Therapeutics reported positive interim Phase 1 data for CTIM-76 in ovarian cancer patients, showing a 29% confirmed overall response rate and a favorable safety profile.
- : Context Therapeutics amended its license with BioAtla to buy out future milestone and royalty obligations for CT-202 in exchange for a $6.5 million payment.
